Rain Therapeutics Inc. (NASDAQ:RAIN) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Rain Oncology Inc. Second Quarter 2023 Earnings Conference Call.
Rain Oncology Inc. (RAIN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Samsara BioCapital Srini Akkaraju And Michael Dybbs | 0 | $0 | 0% | |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 0 | $0 | 0% | |
| 3. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | ||
| 5. | Tang Capital Management Kevin C. Tang | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.99 | 84,145 | Large Shareholder | 4,024,486 | 2023-10-13 | Filing | |
| $0.99 | 47,486 | Large Shareholder | 3,940,341 | 2023-10-13 | Filing | |
| $0.98 | 52,514 | Large Shareholder | 3,892,855 | 2023-10-12 | Filing | |
| $0.98 | 25,188 | Large Shareholder | 3,840,341 | 2023-10-12 | Filing | |
| $0.97 | 74,812 | Large Shareholder | 3,815,153 | 2023-10-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.21 | 40,132 | 3,850,513 | 2023-12-18 | Filing | ||
| $1.20 | 109,435 | 3,890,645 | 2023-12-15 | Filing | ||
| $1.21 | 24,406 | 4,000,080 | 2023-12-14 | Filing | ||
| $1.25 | 995,000 | 1,152,212 | 2023-05-22 | Filing | ||
| $13.40 | 7,306 | Large Shareholder | 2,487,019 | 2021-10-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,349,007 | $1,618,808 | 1.22% | |
| 2. | 1,152,212 | $1,382,654 | 0.06% | |
| 3. | 1,090,707 | $1,308,848 | 0% | |
| 4. | 872,459 | $1,046,951 | 0% | |
| 5. | 410,464 | $539,297 | 0.28% |
News See All
Hedge Fund and Insider Trading News: Ken Griffin, Marshall Wace LLP, Eisler Capital, Sequoia Capital, Arca Capital Management, Diversified Healthcare Trust (DHC), Bank of Hawaii Corp (BOH), and More
A summer internship at Citadel offers perks that include a salary of up to $5,000 a week, free corporate housing in one of 10 different world financial centers like New York and an opening retreat at ...
Rain Therapeutics Inc. (NASDAQ:RAIN) Q1 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Rain Oncology, Inc. First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript
Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded.
Rain Therapeutics Inc. (NASDAQ:RAIN) Q3 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Rain Therapeutics Third Quarter Earnings Conference Call. At this time all participants are in a listen-only mode.
Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs' Samsara BioCapital
In this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs' Samsara BioCapital.
15 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs' Samsara BioCapital
In this article, we will discuss 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs' Samsara BioCapital.
Hedge Fund and Insider Trading News: Nicolai Tangen, Steve Cohen, Starboard Value LP, Legion Partners Asset Management, First Horizon Corp (FHN), Potlatchdeltic Corp (PCH), and More
Legion Partners Asset Management is at it again. The Brentwood-based activist hedge fund is pressing for independent directors on the board of OneSpan Inc.
Hedge Fund and Insider Trading News: Warren Buffett, Jeffrey Talpins, Dan Niles, Amber Capital, Coatue Management, Rain Therapeutics Inc (RAIN), HCA Healthcare Inc (HCA), and More
Laith Khalaf, financial analyst at AJ Bell, shares his analysis on which UK Fund Managers have outperformed Warren Buffett.